Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

StatusUnknown
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jul 2024); last known: Recruiting
  2. Start date: Jul 2006 to Jul 2007
    • Trial status: Recruiting to Unknown
    • Primary completion date: Jul 2007
    • Study completion date: Nov 2006 to Nov 2024
    v4
  3. Site contact updatedv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study completion date: Jun 2006 to Nov 2006
    • Start date: Jun 2006 to Jul 2006
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
Trial Details
NCT Number NCT00346814
Lead Sponsor Asociación para Evitar la Ceguera en México
Conditions
(from sponsor)		 Retinopathy of Prematurity
Related terms Retinopathy of Prematurity
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov